Navigation Links
American Chemical Society's Weekly PressPac -- March 19, 2008
Date:3/24/2008

es, including press releases, non-technical summaries of research presentations, and Internet access to news briefings.

Remote access to media briefings from NOLA via the internet

The ACS Office of Communications is offering news media the opportunity to join press briefings whether covering the meeting onsite or from a remote location. This new updated format in New Orleans will provide access to the increasing number of journalists who cover scientific meetings from their home base. Borrowing the popular chat room concept from the Internet, we will provide news media with access to both real and virtual chat room sessions during the New Orleans meeting. With more than 9,000 research presentations, this is one of the years largest and most significant scientific conferences. Reporters attending the meeting can gather with scientists in an informal setting in our Press Center in Room 206 of the Morial Convention Center. Scientists will summarize their research and field questions. Offsite reporters can enter a virtual version of this Chat Room over the Internet. In addition to seeing and hearing the real-world activity, offsite reporters can submit questions. Click here (http://portal.acs.org/portal/acs/corg/content?_nfpb=true&_pageLabel=PP_ARTICLEMAIN&node_id=222&content_id=WPCP_008471&use_sec=true&sec_url_var=region1) for more information.

ACS Press Releases
http://portal.acs.org/portal/acs/corg/content?_nfpb=true&_pageLabel=PP_ARTICLEMAIN&node_id=222&content_id=CTP_006740&use_sec=true&sec_url_var=region1

General Chemistry Glossary

Contact: Michael Woods
m_woods@acs.org
202-872-4400
American Chemical Society
Source:Eurekalert  

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. Understanding hypertension in African Americans proves elusive
3. Tips from the Journals of the American Society for Microbiology
4. American Chemical Societys Weekly PressPac -- Aug. 15, 2007
5. American College of Medical Genetics responds to new FDA labeling decision for warfarin
6. American Chemical Societys Weekly Press Pac
7. Highlights from the September 2007 Journal of the American Dietetic Association
8. American Chemical Societys Weekly Presspac -- Aug. 29, 2007
9. Report: African, Asian, Latin American farm animals face extinction
10. American Chemical Society calls green chemistry bill a smart step
11. Challenges remain in reintroducing American chestnut
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
American Chemical Society's Weekly PressPac -- March 19, 2008
American Chemical Society's Weekly PressPac -- March 19, 2008
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2Miami Health Insurance Outlook and Update 54523 1Miami Health Insurance Outlook and Update 54523 2Miami Health Insurance Outlook and Update 54523 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 1Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 2Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 4Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 5Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 6Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 7Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 8Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 9Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 10Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 11Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 12Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 13
...ss announces the latest edition of an essential ...pidly changing fields of clinical medicine. Coveri...nosis, treatment, and prevention, Clinical Virolo...ls about all the medically relevant aspects of thi...tly one of the most dynamic areas of clinical medi...
...helle, NY, March 17, 2009While the Bernard Madoff ...undation, a major benefactor for life science rese...from the scandal as a minor consequence in the lar... & Biotechnology News (GEN). They look at the Mad... global financial environment that has been rocked...
... human papilloma virus (HPV)-infections can lead t...-stage to cervical cancer. Surgical treatment of t... birth in subsequent pregnancies. As the HPV-vacci...ay therefore reduce the number of preterm births. ...of HPV-vaccination. , Cervical cancer developmen...
Other Biology News:New edition available for essential virology reference 2GEN reports on Madoff scandal's impact on the life sciences 2HPV vaccine may prevent preterm births 2
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... PARK, Calif., May 27 ForteBio(R), Inc., a leadin...es the development of biotherapeutic and pharmaceu...ed two new assay modules - for high-sensitivity pr...ively - for use on the company,s Octet(R) instrume...a software upgrades and will enable, for the first...
...LL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall...I ) announced today that the Company will hold a l...ade at an OncoGenex hosted reception during the 20...eting (ASCO) on Saturday, May 30, 2009. The webcas...ion, OncoGenex management and guest speakers will ...
...arch has shown that certain marginalized groups i... minorities such as African Americans and Latinos ...l disasters, suffering disproportionate impoverish...udy by UCLA researchers and colleagues has found t... fears and make more behavioral changes based on t...
Other Biology Technology:ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
...be gel adaptors, 24 glass tubes (1.5 mm ID, 180 mm... II xi cell and PROTEAN II XL wide-format cell off...ions,* including SDS-PAGE, first- and second-dimen... gradient PAGE as well as high-resolution agarose ...
SVT3-2 Diverter Valve from Bio-Rad
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
Biology Products: